Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: Possible link to serum anti-endothelial cell antibodies

Clinical and Experimental Immunology

Volumn 167, Issue 3, 2012, Pages 532-542

  Sato, Y ^a   Ren, X S ^a   Harada, K ^a   Sasaki, M ^a   Morikawa, H ^b   Shiomi, S ^b   Honda, M ^a   Kaneko, S ^a   Nakanuma, Y ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti endothelial cell antibody; Elastin; Hepatoportal sclerosis; Idiopathic portal hypertension; Obliterative portal venopathy

Indexed keywords

CALVASCULIN; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; ENDOTHELIAL CELL ANTIBODY; FIBRILLIN 1; FIBRONECTIN; FIBULIN 5; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCLEROSIS;

APOPTOSIS; AUTOANTIBODIES; BASE SEQUENCE; CASE-CONTROL STUDIES; CELLS, CULTURED; DNA PRIMERS; ELASTIN; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PORTAL; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; PANCYTOPENIA; PORTAL VEIN; RNA, MESSENGER; SCLEROSIS; SPLENOMEGALY;

EID: 84856400724     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04530.x     Document Type: Article

References (31)

1. Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 2001; 197:65-76.
2. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54:1071-81.
3. Nakanuma Y, Hoso M, Sasaki M etal. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195-204.
4. Nakanuma Y, Nonomura A, Hayashi M etal. Pathology of the liver in 'idiopathic portal hypertension' associated with autoimmune disease. The Ministry of Health and Welfare Disorders of Portal Circulation Research Committee. Acta Pathol Jpn 1989; 39:586-92.
5. Tsuneyama K, Harada K, Katayanagi K etal. Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J Gastroenterol Hepatol 2002; 17:217-23.
6. Nakanuma Y, Sato Y, Kiktao A. Pathology and pathogenesis of portal venopathy in idiopathic portal hypertension: hints from systemic sclerosis. Hepatol Res 2009; 39:1023-31.
7. Saito K, Nakanuma Y, Takegoshi K etal. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology 1993; 40:163-6.
8. Terada T, Nakanuma Y, Obata H. HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis. Arch Pathol Lab Med 1991; 115:993-7.
9. Tokushige K, Yamauchi K, Komatsu T, Takasaki K, Hayashi N. Predominant T helper 1 cells in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 2000; 15:1312-17.
10. Kitao A, Sato Y, Sawada-Kitamura S etal. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol 2009; 175:616-26.
11. Karasek MA. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease? Med Hypotheses 2007; 68:650-5.
12. Sato Y, Sawada S, Nakanuma Y. Fibulin-5 is involved in phlebosclerosis of major portal vein branches associated with elastic fiber deposition in idiopathic portal hypertension. Hepatol Res 2008; 38:166-73.
13. Praprotnik S, Blank M, Meroni PL, Rozman B, Eldor A, Shoenfeld Y. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum 2001; 44:1484-94.
14. Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 2010; 69:319-24.
15. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008; 38:132-60.
16. Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006; 54:2250-62.
17. Yang YH, Wang SJ, Chuang YH, Lin YT, Chiang BL. The level of immunoglobulin A antibodies to human umbilical vein endothelial cells can be enhanced by tumour necrosis factor-alpha treatment in children with Henoch-Schonlein purpura. Clin Exp Immunol 2002; 130:352-7.
18. Sawada S, Sato Y, Aoyama H, Harada K, Nakanuma Y. Pathological study of idiopathic portal hypertension with an emphasis on cause of death based on records of Annuals of Pathological Autopsy Cases in Japan. J Gastroenterol Hepatol 2007; 22:204-9.
19. Tsutsumi Y, Kawai K, Nagakura K. Use of patients' sera for immunoperoxidase demonstration of infectious agents in paraffin sections. Acta Pathol Jpn 1991; 41:673-9.
20. Servettaz A, Guilpain P, Tamas N, Kaveri SV, Camoin L, Mouthon L. Natural anti-endothelial cell antibodies. Autoimmun Rev 2008; 7:426-30.
21. Youinou P. New target antigens for anti-endothelial cell antibodies. Immunobiology 2005; 210:789-97.
22. Servettaz A, Guilpain P, Camoin L etal. Identification of target antigens of antiendothelial cell antibodies in healthy individuals: a proteomic approach. Proteomics 2008; 8:1000-8.
23. Karasawa R, Kurokawa MS, Yudoh K, Masuko K, Ozaki S, Kato T. Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis. Clin Exp Immunol 2010; 161:459-70.
24. Bordron A, Dueymes M, Levy Y etal. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998; 101:2029-35.
25. Tobon GJ, Alard JE, Youinou P, Jamin C. Are autoantibodies triggering endothelial cell apoptosis really pathogenic? Autoimmun Rev 2009; 8:605-10.
26. Laplante P, Sirois I, Raymond MA etal. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ 2010; 17:291-303.
27. Tsuneyama K, Kouda W, Nakanuma Y. Portal and parenchymal alterations of the liver in idiopathic portal hypertension: a histological and immunochemical study. Pathol Res Pract 2002; 198:597-603.
28. Morikawa H, Tamori A, Nishiguchi S etal. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007; 13:240-5.
29. Papa ND, Raschi E, Moroni G etal. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus 1999; 8:423-9.
30. Yamaguchi N, Tokushige K, Haruta I, Yamauchi K, Hayashi N. Analysis of adhesion molecules in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1999; 14:364-9.
31. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214:199-210.